Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
11
×
life sciences
national blog main
clinical trials
boston
national top stories
fda
san francisco blog main
deals
new york blog main
startups
san diego blog main
san francisco top stories
cancer
europe blog main
investing
new york top stories
san diego top stories
atlas venture
biofourmis
black diamond therapeutics
boulder/denver blog main
boulder/denver top stories
chronic rhinosinusitis
decibel therapeutics
detroit blog main
detroit top stories
dyne therapeutics
eli lilly
europe top stories
flagship pioneering
gene therapy
glaxosmithkline
indiana blog main
indiana top stories
ipo
kaleido biosciences
laurence reid
What
therapeutics
11
×
medicines
drug
ipo
new
ago
biotech
developing
million
raised
treat
approval
black
clinic
companies
company
data
debut
diamond
drugs
dyne
fda
genetic
late
leading
muscle
rare
research
startup
targets
therapy
won
years
adding
address
adds
agency
aiming
aimmune
aims
Language
unset
11
×
Current search:
unset
×
" boston top stories "
×
therapeutics
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further